Introduction
============

The tumor suppressor gene *Hypermethylated in Cancer 1 (HIC1)* is inactivated by CpG island hypermethylation in a variety of human cancers ([@bib42]). *HIC1* resides in a region of chromosome 17p13 frequently targeted for allelic loss in human cancer ([@bib42]). This region is also associated with the Miller--Dieker Syndrome, a congenital disorder characterized by severe facial and neurologic deficits ([@bib10]; [@bib13]). Homozygous deletion of *Hic1* in mice results in major developmental defects and embryonic lethality ([@bib10]). *HIC1* heterozygous mice retaining one allele of *Hic1,* develop age- and gender-dependent tumors associated with promoter hypermethylation and gene silencing of the remaining wild type (WT) *HIC1* allele ([@bib13], [@bib11]; [@bib9]). These studies suggest that *Hic1* has important roles both in development and tumor suppression.

Mutations in the *adenomatous polyposis coli* (*APC)* gene have been implicated both in familial as well as sporadic gastrointestinal (GI) cancers. *APC* mutations are associated with autosomal dominant inheritance of disease in humans. Similarly, mice that contain a single mutant *Apc* gene encoding a protein truncated at amino acid residue 716 (*Apc*^Δ*716*^) develop multiple polyps throughout the GI tract as early as 4 weeks after birth ([@bib31]; [@bib43]). A major function of APC in human cells is to regulate Wnt signaling in stem cells and cancer by preventing the nuclear translocation of β-catenin (reviewed in ([@bib22]; [@bib37])). As expected, polyps derived from mice with a disruption in Apc function (*Apc*^*min*^ and *Apc*^Δ*716*^ ), display nuclear β-catenin, typically associated with dysregulated Wnt signaling ([@bib39]; [@bib31]).

Hic1 is a sequence-specific transcriptional repressor with an N-terminal POZ domain, and five C~2~H~2~ zinc-fingers at the C-terminus ([@bib15], [@bib14], [@bib16]). A growing body of evidence suggests that one important function of HIC1 is to inhibit the canonical Wnt signaling pathway. Recent studies in mammalian cell lines suggest that HIC1 antagonizes Wnt signaling through association with TCF4 and β-catenin in a transcriptionally inactive complex retained in the nucleus ([@bib40]). Moreover, our previous studies have shown that knockdown of SIRT1, an important repressive target of HIC1 ([@bib12]), in breast and colon cancer cells leads to the reactivation of the epigenetically silenced Wnt antagonists, sFRPs ([@bib36]). Together, these data suggest that Hic1 can also fine-tune the Wnt pathway in cancer cells.

We now report that loss of a single *Hic1* allele can promote crypt hyperplasia of the small intestine and further potentiate polyp formation in *Apc*^+/Δ*716*^ mice. *Hic1*^+/−^, *Apc*^+/Δ*716*^ double heterozygous (DH) mice develop increased numbers of polyps throughout the GI tract by 60 days. Hic1 is not expressed in polyps with an increase in DNA, and immunohistochemical analyses of polyps show increases in markers such as β-catenin, Sirt1 and Sox9, indicating aberrant Wnt and Hic1 signaling. Together, our data suggest that loss of a gene frequently silenced via epigenetic mechanisms, *Hic1*, can cooperate with loss of a gene often mutated in GI cancer, *Apc*, to promote tumorigenesis in an *in vivo* model of multiple intestinal neoplasia.

Results
=======

DH mice develop increased numbers of polyps throughout the GI tract
-------------------------------------------------------------------

Loss of a single *Hic1* allele complements loss of Apc function to promote acceleration of polyp formation in 60-day-old Hic1^+/−^, Apc^+/−^ mice. In all four genotypes generated from the cross between *Hic1*^+/−^ females and *Apc*^+/Δ*716*^ male mice, the greatest numbers of polyps in both the small ([Figures 1a and d](#fig1){ref-type="fig"}) and large ([Figures 1b and d](#fig1){ref-type="fig"}) intestines were present in the GI tracts of DH mice. At this age, no polyps were detected in *Hic1*^+/−^ mice, and WT controls do not develop polyps at any age studied. *Hic1*^+/−^ mice do, however, develop a few polyps by 90 days of age, but the number of tumors is greater in *Apc*^+/Δ*716*^ and DH mice (Supplementary Figure S1). At 60 days, the majority of polyps in *Apc*^+/Δ*716*^ mice were found in the small intestine, as reported previously ([@bib31]), and the size is predominantly small (\<2 mm) ([Figures 2a--d](#fig2){ref-type="fig"}). DH mice, however, develop increased numbers of polyps throughout all regions of the small and large intestine ([Figures 2a--d](#fig2){ref-type="fig"}). Notably, in the large intestine, there were several large polyps over 2 and 3 mm in DH, with none greater than 3 mm in the single *Apc*^+/Δ*716*^ ([Figure 2d](#fig2){ref-type="fig"}). This involvement of the colon is more reminiscent of the spectrum of human GI cancers.

Sirt1 and Hic1 expression are inverse to one another in normal GI tissue
------------------------------------------------------------------------

Immunohistochemical analyses reveal that in WT mice Hic1 expression is largely restricted to the stromal and inflammatory cells in lamina propria in the small intestine, with only occasional nuclear staining in epithelial cells ([Figure 3a](#fig3){ref-type="fig"}). By real-time PCR analysis of Hic1 expression within the small intestine, within some variability in levels, values were not statistically different for WT and Hic1^+/−^ mice ([Figure 3e](#fig3){ref-type="fig"}). However, there is a statistically significant change in terms of decreased Hic1 expression in DH mice ([Figure 3e](#fig3){ref-type="fig"}). In the colon, by immunohistochemistry, Hic1 is highly visible in cells in the upper crypt and intercrypt table containing more mature epithelial cells ([Figure 3b](#fig3){ref-type="fig"}), whereas it is low to undetectable near the base of the colonic crypts, where progenitor cells reside ([@bib35]; [@bib2], [@bib1]).

In this above setting, we examined the distribution of nuclear Sirt1, a transcription repression target of Hic1 ([@bib12]). In the small intestine, the protein is expressed throughout the progenitor crypt regions and mature villus epithelial cells ([Figure 3c](#fig3){ref-type="fig"}). In *Hic1*^+/−^ mice and DH mice, which have only one functional copy of *Hic1,* the distribution of Sirt1 remains unchanged, but there is a distinct increase in the intensity of Sirt1 staining throughout the crypt and mature villus epithelial region. A much more striking inverse pattern for Hic1 and Sirt1 is observed in normal mouse colon mucosa. Hic1 expression in the large intestine is highest in WT animals, whereas the lowest expression appears to be restricted to mice that have only one functional allele of *Hic1* (*Hic1*^+/−^ and DH) ([Figure 3b](#fig3){ref-type="fig"}). Furthermore, in the WT mice, Hic1 expression is inverse to that of Sirt1, which is more restricted to colonic basal crypt regions, and its expression gradually decreases as cells migrate toward the upper crypt, where the cells express Hic1 ([Figure 3d](#fig3){ref-type="fig"}). Inverse to the decreased Hic1 expression in mice with one functional *Hic1* allele, Sirt1 expression throughout the large intestine appears to have regionally expanded to the more mature cells above the upper crypt in *Hic1*^+/−^ and DH mice ([Figures 3b and d](#fig3){ref-type="fig"}). Together, these data suggest that Hic1 and Sirt1 maintain an inverse relationship in the GI tract and, notably, that the reduction in Hic1 expression in the GI tract of *Hic1*^+/−^ and DH mice conveys a functional consequence for Sirt1 distribution in this tissue.

Hic1 methylation in normal and neoplastic tissue
------------------------------------------------

In previous settings, loss of *Hic1* expression in tumors in *Hic1*^+/−^ mice, and in many human tumors ([@bib21]; [@bib17]), has been associated with DNA hypermethylation of either an upstream (Hic1a) or downstream (Hic1b) promoter region ([@bib13]). Both regions are associated with exons, which are transcribed ([@bib23]), and hypermethylation of either can correlate with complete loss of transcripts for the gene ([@bib13]; [@bib9]). As detailed in the earlier studies, bisulfite sequence analysis can distinguish the WT Hic1b region from the targeted allele, but cannot separate WT Hic1a from the disrupted allele ([@bib13]; [@bib9]). To elucidate whether methylation may have a role in the reduced Hic1 expression in the small and large intestine, as described, or in the increased polyps observed in DH animals, we assessed the methylation status of Hic1 in the current study using bisulfite sequence analysis, as described previously ([@bib13]; [@bib9]). Although the overall density of methylation is not dramatic, we do observe the greatest increase in methylation for *Hic1a*, both in polyps from the small and large intestine of DH mice relative to WT animals as well as *Apc*^+/Δ*716*^ ([Figures 4a and b](#fig4){ref-type="fig"}). Interestingly, normal small intestine from *Hic1*^+/−^ as well as from DH animals also displays greater methylation relative to WT animals ([Figure 4b](#fig4){ref-type="fig"}), corresponding to the decreased expression observed by real-time PCR ([Figure 3e](#fig3){ref-type="fig"}). The WT Hic1b region, however, is variably more methylated than Hic1a in both the normal small and large intestines in mice of all genotypes ([Figures 4c and d](#fig4){ref-type="fig"}). As noted above, there is minimal detectable expression of Hic1 ([Figure 3a](#fig3){ref-type="fig"}) in normal small intestine, but this low level appears to be further reduced in the DH animals ([Figure 3e](#fig3){ref-type="fig"}).

Hic1 heterozygotes develop crypt hyperplasia
--------------------------------------------

Despite the lack of significant Hic1 expression in the small intestine, it remains clear that the genetic loss of a single Hic1 allele potentiates polyp development. A key finding that may provide some additional insight into the acceleration of polyps in DH mice within the small intestine emerged when we analyzed the proliferation status of the GI tract. Ki67, a hallmark of proliferation, ([@bib4]), was positive in all polyps examined (data not shown) and, as expected, restricted to the more proliferative cells in the normal intestinal crypts ([Figure 5a](#fig5){ref-type="fig"}). Interestingly, the loss of a single *Hic1* allele leads to crypt hyperplasia. This hyperplasia manifests, in *Hic1*^+/−^ and DH mice, as increased numbers of crypts per villi ([Figures 5a and b](#fig5){ref-type="fig"}). No obvious changes in the total number of villi were observed. These hyperplastic crypts have little or no Hic1, whereas Sirt1 expression is abundant ([Figure 3](#fig3){ref-type="fig"}). We examined crypts from all genotypes for potential alterations in the progenitor cell marker, Lgr5 ([@bib3]), and found similar numbers of Lgr5 positive cells, suggesting no direct effect of Hic1 allelic loss on this sub-population within each crypt unit (data not shown). However, we did find features associated with crypt dysplasia ([@bib24]) in *Hic1*^+/−^ small intestines (Supplementary Figure S2), as well as a small number of polyps (Supplementary Figure S1). This suggests that the loss of Hic1 alone may be significant in the development of GI tumors at this early age and, as previously observed, in much older animals as well ([@bib13]).

Polyps do not express Hic1 and display hallmarks of aberrant Hic1 and Wnt signaling
-----------------------------------------------------------------------------------

As expected, based on the increase in methylation observed for Hic1a in both the large and small intestine ([Figure 4](#fig4){ref-type="fig"}) and the absence of Hic1 expression in normal small intestine, polyps from *Hic1*^+/−^ and DH mice did not express detectable Hic1 ([Figure 6a](#fig6){ref-type="fig"}). Small intestine polyps from *Apc*^+/Δ*716*^ also did not express Hic1 ([Figure 6a](#fig6){ref-type="fig"}). In the normal and neoplastic tissue from *Apc*^+/Δ*716*^ mice, however, this may be due to a chromatin-based repressive mechanism surrounding the Hic1a region, as there was no increase in DNA methylation for this genotype ([Figure 4](#fig4){ref-type="fig"}). *Apc*^+/Δ*716*^ polyps and tumors from DH mice showed nuclear β-catenin, a hallmark of increased Wnt signaling ([@bib34]) ([Figure 6a](#fig6){ref-type="fig"}). Interestingly, polyps from *Hic1*^+/−^ mice also contained nuclear β-catenin, suggesting that Wnt signaling is also hyperactive in the neoplasms from this genotype ([Figure 6a](#fig6){ref-type="fig"}).

As polyps derived from *Hic1*^+/−^, *Apc*^+/Δ*716*^ and DH mice had no detectable Hic1 expression, we next examined polyps expression of known transcriptional repression targets of Hic1. As described previously ([@bib12]) and above, Sirt1 expression is inversely related to the presence of Hic1 in normal GI. We find that, concordant with the absence of Hic1, Sirt1 expression is retained in polyps across all genotypes ([Figure 6a](#fig6){ref-type="fig"}).

We further extended our analysis to Sox9, reported as having reduced gene expression in a microarray screen following Hic1 overexpression in U2OS osteosarcoma cells ([@bib41]). Sox9 is a transcription factor found in Paneth cells as well as progenitor cells in intestinal crypts ([@bib5]). As the above array data was not verified or characterized, we first validated that Sox9 is truly a Hic1 target gene and that this relationship exists in the GI. As analyzed by immunohistochemistry, Sox9 expression, similar to Sirt1 in normal large intestine, is inverse to the distribution of Hic1 (Supplementary Figure S3). This protein is also restricted to the nuclei of crypt cells and decreases in more mature cells that express Hic1. Also, like Sirt1, Sox9 was highly expressed in all polyps from *Hic1*^+/−^, *Apc*^+/Δ*716*^ and DH mice coupled with the absence of Hic1 expression ([Figure 6d](#fig6){ref-type="fig"}). Analysis of the sequence provided by the UCSC genome browser revealed the presence of several potential Hic1-binding sites ([@bib33]; [@bib12]) upstream of the SOX9 transcriptional start site. Sox9 expression was increased by greater than twofold in knockout *Hic1*^−*/*−^ MEFs ([Figure 6b](#fig6){ref-type="fig"}). Additionally, SOX9 was repressed upon ectopic overexpression of Hic1 in HCT116 human colon cancer cells that do not express endogenous Hic1 ([Figure 6c](#fig6){ref-type="fig"}). Chromatin immunoprecipitation (ChIP)of the ectopically expressed protein to several of the sequence-binding regions for HiC1 upstream of the SOX9 gene correlated with this finding (Supplementary Figure S4).

Discussion
==========

In the current study, we have established a mouse model in which loss of function for *Hic1* augments the role of *Apc* loss for development of GI tumors. Importantly, this effect of *Hic1* loss of function accentuates not only the tumorigenesis in the small intestine, which dominates in *Apc*^+/Δ*716*^ mice, but also increases both the number and size of polyps in the large intestine. These results are consistent with our previous work, indicating that Hic1 can serve a tumor-suppressive function through a variety of important mechanisms involving its role for transcriptional repression of multiple downstream targets ([@bib10]; [@bib13], [@bib11]; [@bib9]).

The role of *Hic1* in the above model may be to provide a cellular setting that provides *Apc* loss an optimal opportunity for exerting an oncogenic stimulus. Recently, Clevers *et al.* have shown that loss of Apc in mouse intestine is most tumorigenic when engineered to target intestinal stem cells ([@bib1]). The loss of one *Hic1* allele appears to increase the number of stem cell-containing crypt cell compartments and lead to some dyplastic features in these regions. This scenario may thus increase the target cell population susceptible to the oncogenic effects of *Apc* disruption. Presumably, this setting may favor the addiction of intestinal stem cells to increased Wnt pathway activity driven by loss of Apc function. Interestingly*, Hic1*^+/−^ mice also develop polyps (Supplementary Figure S1), and spontaneous GI cancers appear in older *Hic1*^+/−^ animals ([@bib13]), suggesting that the crypt hyperplasia and dysplasia are significant even without the additional genetic contribution from *Apc*^+/Δ*716*^.

Hic1 is not only a critical developmental protein, but is emblematic, for human cancers, of a tumor suppressor gene for which loss of function arises through epigenetic rather than genetic alterations ([@bib42]). Loss of Hic1 expression in colon cancer, specifically, has also been associated with silencing associated with DNA hypermethylation ([@bib30]) ([@bib27]). In the particular mouse model described here, the mechanism for the silencing of the remaining WT allele of Hic1 in tumors is not yet as clear as in previous studies of our *Hic1* heterozygous mice ([@bib13]; [@bib9]). In our earlier work, dense methylation of the proximal promoter of the WT allele of the gene has almost always been present in the different tumor types that arise in these mice alone, or when they are crossed with other tumor-prone mice ([@bib11]; [@bib9]). In the present case, the increases we find in tumors for *Hic1* promoter DNA methylation are quite small in both promoter regions studied. Although these changes may still be significant for loss of gene transcription, they accompany other chromatin changes that aid in gene silencing.

Another puzzling feature for expression of Hic1 in our model is the difference between normal small and large intestine. In the latter, a clear pattern is present, wherein Hic1 is expressed in the more differentiated cells of the more luminal region, whereas, interestingly, the transcriptional repression targets we studied, Sirt1 and Sox 9, are expressed in the stem cell-containing crypt regions. These latter proteins seem to lose this regional distribution in the *Hic1* heterozygous mice, consistent with a modulatory role for Hic1 in their expression patterns. However, despite the clear crypt region changes we observe in the small intestine of the *Hic1*^+/−^ mice, Hic1 protein expression is below detection by immunohistochemistry in the epithelial cells. However, there is a reduction in Hic1 mRNA expression in DH animals by real-time PCR. Thus, we suspect that a small amount of protein may be functional in this region, because loss of a single WT *Hic1* allele affects the number of small intestine crypts, causing some changes in Sirt1 and Sox9 expression patterns, and clearly complements tumorigenicity in the DH animals.

Previous studies from others, as well as our work, have identified a number of relevant targets of Hic1 in a variety of biological contexts. In the cerebellum of mice, loss of this protein leads to increased levels of the downstream repression target gene, *Atonal Homolog 1*. These changes complement loss of the Sonic Hedgehog receptor, *PATCHED*, to increase the numbers of progenitor cells and augment cerebellar tumorigenesis ([@bib9]). Hic1 loss also associates with spatial disruption of the downstream repression target, ephrin A1 ([@bib44]), which is a key patterning morphogen in development. However, in our present model, the molecular mechanisms by which Hic 1 loss exerts changes in the intestine are not yet clear. As we show, two known repression target genes of Hic1, Sirt1 ([@bib12]) and Sox9 ([@bib41]) are both highly expressed in nuclei of tumor cells in the *Hic1*^+/−^*, Apc*^+/−^ mice. Sirt1, a mammalian ortholog of the yeast Sir2 protein, is a direct transcriptional target of Hic1 ([@bib12]). The role for Sirt1 in tumorigenesis has proven substantially complex to understand as both *Sirt1* knockout and overexpression systems have yielded discordant results. A study in which *Sirt1* knockout animals were crossed to *Apc*^*min*/+^ mice showed that loss of Sirt1 had no effect on polyp number in *Apc*^*min*/+^ animals, but that polyp size was decreased ([@bib7]). These data suggest a pro-tumorigenic role for Sirt1 in this system. Additional work has recently linked Sirt1 to repression of the Wnt inhibitors, disheveled, providing an additional Wnt-related mechanism by which Sirt1 may promote tumorigenesis ([@bib25]). However, another study showed the opposite effect, in that polyps were decreased in *Apc*^*min*/+^ animals upon overexpression of Sirt1 in the intestine ([@bib19]). Although the role for Sirt1 in GI tumor initiation and progression may remain controversial, in our current study, significant Sirt1 expression is present in all polyps and inversely correlates with Hic1 expression. Thus, either the protein has an oncogenic role in this setting or, if it is a tumor suppressor, it is ineffectual because of lack of signaling to downstream targets.

Sox9 has been shown to be repressed by greater than threefold in U2OS osteosarcoma cells infected with Ad-HIC1 ([@bib41]). In this regard, we now confirm *Sox9* as a direct Hic1 target gene for transcriptional repression in human colon cancer cells and mouse MEFs by both expression analysis and ChIP. This high-mobility group box transcription factor has been described in the GI tract as a Wnt pathway target ([@bib6]) and, thus, this gene may be co-regulated by both Hic1 and Wnt signaling. Sox9 expression appears to positively correlate with β-catenin expression in human colorectal cancer ([@bib26]). A recent study also showed that SOX9 represses expression of protein kinase C alpha in proliferating intestinal epithelial cells ([@bib18]), a gene that, in *Apc*^*min*/+^ mice, may provide a protective role against intestinal tumorigenesis ([@bib32]). Sox9 serves as an important crypt-related transcription factor through its ability to repress genes associated with differentiation ([@bib6]), and an imbalance in Sox9 expression gives rise to crypt dysplasia ([@bib5]). This may be tightly tied to our current finding that crypt hyperplasia is coupled with crypt dysplasia in our Hic1^+/−^ mice.

In summary, we describe, in a mouse model, an oncogenic interaction between loss of function for the *Hic1* and *Apc* genes. This complementation appears fueled by increases in crypt cell regions due to the *Hic1* disruption. We associate increases in two Hic1 transcriptional repression targets, *Sirt1* and *Sox9*, with changes in the above model, but their direct roles remain to be defined for the tumorigenic events studied. Our mouse model will prove extremely valuable for exploring this and other questions linking Hic1 and the Wnt pathway to intestinal tumorigenesis.

Materials and methods
=====================

Mice
----

Mice were housed in a pathogen-free environment and observed daily for signs of ill health. *Hic1*^+/−^ females were crossed to *Apc*^+/Δ*716*^ males to generate mice used in the studies described. Both strains were backcrossed as described previously ([@bib31]; [@bib13]; [@bib9]) and maintained in a C57BL/6 background. Genotyping was performed as described previously ([@bib31]; [@bib10]).

Polyp counts
------------

Mice were killed at 60 or 90 days by CO~2~ asphyxiation. The intestinal tract was removed, opened longitudinally and washed with PBS, as described previously ([@bib29]). The cleared tissue was fixed in 10% buffered formalin and subsequently stained with 1.5% methylene blue in physiological saline (0.9%). Intestines were destained with 10% ethanol using several changes of fresh destaining solution to attain the desired level of stain. At this level, intestinal tissue appeared light blue with significantly darker polyps. The proximal, medial and distal regions of the small intestine and the entire large intestine were examined. Polyps were scored with a dissecting microscope by at least two independent observers, and the average counts were further analyzed. Student\'s *t*-test was used to compare the mean allele count between DH and Apc for 60 days by anatomical regions and subregions. All comparisons were considered statistically significant at a *P*-value \<0.05 (\*) or *P*-value \<0.1 (\*\*). All statistical analyses were performed using Stata 10 statistical package.

Immunohistochemistry
--------------------

Hic1 immunohistochemistry was performed as previously described ([@bib13]). Antigen retrieval for deparaffinized tissue sections was performed in citrate buffer (small intestine) or Tris-EDTA buffer (colon) for 20 min by using a steamer. Following blocking of endogenous peroxidase, paraffin-embedded sections were submitted to immunohistochemistry using the Vectastain Elite ABC system (Vector Laboratories, Burlingame, CA, USA). Citrate buffer antigen retrieval and Vectastain ABC kits (Vector Laboratories) were used for all other immunohistochemistry. The following antibodies were used: Sox9 (Chemicon, Billerica, MA, USA), β-Catenin (BD Transduction Laboratories, Sparks, MD, USA), Ki67 (Novocastra Laboratories, Newcastle upon Tyne, UK) and Sirt1 (Upstate Biotechnology, Billerica, MA, USA).

Crypt counting
--------------

Ki67 staining was used to mark crypt cells within sections prepared, as described above. Images were collected at × 20 magnification throughout the small intestine, and at least 21 fields from 4 mice across all genotypes were utilized. Crypt hyperplasia was documented by counting crypts as described previously with some modification ([@bib38]; [@bib8]). In the current study, the number of crypts and intestinal villi were counted for each image by two independent observers, and the average of the two counts was used in the data analysis.

Bisulfite sequencing
--------------------

Genomic DNA extraction and bisulfite modification, and sequencing of tissue derived from WT, *Hic1*^+/−^, *Apc*^+/Δ*716*^ and DH mice was performed as previously described ([@bib20]; [@bib13]). Primers used were within Hic1a and 1b promoters as previously described ([@bib13]). Sequences are available upon request. An average of 68 alleles was sequenced for each genotype for Hic1a, whereas an average of 20 alleles for each was analyzed for Hic1b. Weighted means were generated and statistical analyses performed are as follows: the generalized estimating equation data analysis, assuming independent correlation structure with robust standard error estimates and Gaussian distribution was used to calculate the mean percent methylation per allele, and corresponding standard errors for each genotype. To control for multiple testing, Sidak adjustment method was used to correct for family-wise error rate. All statistical analyses were performed using Stata version 10 statistical package and are shown in Supplementary Table 2.

Preparation of MEFs
-------------------

MEFs from E10.5 mouse embryos were prepared as described previously ([@bib9]). Early passage (p2) MEFs were seeded at a density of 2 × 10^5^ per well in a six-well plate. The cells were maintained in DMEM (Cellgro, Manassas, VA, USA) supplemented with 10% bovine calf serum (HyClone, Hudson, NH, USA) and antibiotics, and grown at 37 °C in 5% CO~2~ atmosphere.

RNA preparation and real-time analysis
--------------------------------------

Total RNA was isolated from cell pellets and DNase 1 treated using RNeasy (Qiagen, Valencia, CA, USA). Real-time PCR was performed using conditions and primers described previously, including initial normalization to GAPDH.

Cell culture
------------

Cell lines were maintained according to ATCC guidelines. All transfections were performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), according to manufacturer\'s instructions.

Western analysis
----------------

Antibodies used were: Sox9 (Chemicon) and V5 (Invitrogen). β-Actin (Sigma, St Louis, MO, USA) was used as a loading control.

ChIP
----

ChIP was carried out on HCT116 cells transfected as described above. ChIP was performed as described previously ([@bib28]) using V5 antibody (Invitrogen) or IgG control (Millipore, Billerica, MA, USA).
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![DH mice develop more polyps than Apc mice. (**a**) Methylene blue staining of intestinal sprays collected from small intestines of WT, *Apc*^+/Δ*716*^(Apc), *Hic1*^+/−^ (Hic1), and DH *Apc*^+/Δ*716*^*, Hic1*^+/−^ (DH) mice at 60 days. Sample sizes were as follows: WT, *n*=12; Hic1, *n*=13; Apc, *n*=7; DH, *n*=8. Arrows indicate polyps. (**b**) Methylene blue staining of intestinal sprays collected from large intestines of WT, Apc, Hic1 and DH mice at 60 days. Arrows indicate polyps. (**c**) Values represent the mean number of polyps±s.e.m. throughout the entire GI tract as counted under a dissection microscope. (**d**) Values represent the mean number of polyps±s.e.m. in the small or large intestine as indicated. Statistics were carried out as detailed in materials and methods. Comparisons were considered statistically significant at a \**P*-value \<0.05.](onc2010633f1){#fig1}

![DH mice have more polyps of all sizes in all regions of the GI tract. (**a**) Values represent the mean number of polyps±s.e.m. throughout the proximal small intestine or duodenum counted at 60 days. Polyp size ranges are as indicated. White and black columns indicate *Apc*^+/Δ*716*^ and DH (respectively). (**b**) Values represent the mean number of polyps±s.e.m. throughout the medial small intestine or jejunem. Polyp size ranges are as indicated. White and black columns indicate Apc and DH (respectively). (**c**) Values represent the mean number of polyps±s.e.m. throughout the distal small intestine or ileum. Polyp size ranges are as indicated. White and black columns indicate Apc and DH (respectively). (**d**) Values represent the mean number of polyps±s.e.m. throughout the large intestine or colon. Polyp size ranges are as indicated. White and black columns indicate Apc and DH (respectively). Statistics were carried out as detailed in materials and methods. Comparisons were considered statistically significant at a \**P*-value \<0.05 or \*\**P*-value \<0.1.](onc2010633f2){#fig2}

![Hic1 and Sirt1 expression throughout the GI tract. (**a**) Hic1 immunohistochemistry of paraffin-embedded small intestine sections from mice as indicated. (**b**) Hic1 immunohistochemistry of paraffin-embedded large intestine sections. (**c**) Sirt1 immunohistochemistry of paraffin-embedded small intestine. (**d**) Sirt1 immunohistochemistry of paraffin-embedded large intestine. Genotypes of mice are as indicated for all panels. Scale bar=50 μm for all panels. (**e**) Realtime PCR expression of Hic1 in small intestine. Values represent the mean fold change±s.e.m. for triplicates relative to actin. Genotypes of animals are as indicated. Tissue was analyzed from two WT animals, three Hic1, three Min and three DH (\**P*\<0.05).](onc2010633f3){#fig3}

![Hic1 methylation analysis by bisulfite sequencing. (**a**) Left panel: representative alleles for *Hic1a* for bisulfite sequencing of DNA from normal small intestine and small intestine polyps. Each square along a horizontal row=a CpG site in a TA cloned allele with white=unmethylated and black=methylated. Alleles are from non-polyp DNA from WT (W), *Hic1*^+/−^ (H), *Apc*^+/Δ*716*^ (A), polyps from *Apc*^+/Δ*716*^ (AP), non-polyp DH mice (D) and DH polyps (DP), respectively. Right panel: shown are representative alleles for Hic1a in normal large intestine and large intestine polyp DNA (right) with alleles listed as for left panel. (**b**) Percent methylation (*Y*-axis),with bars=±s.e.m., per alleles shown in A and, on the *X* axis, 1=W, 2=H, 3=A, 4=AP, 5=D and 6=DP. An average of 68 alleles was sequenced for each genotype. (**c**) Representative alleles for *Hic1b* bisulfite sequencing in the small intestine (left), and large intestine (right), respectively, with allele symbols as in A. (**d**) Percent methylation per allele for *Hic1b* with axes and symbols exactly as in B. For all graphs: \**P*\<0.05 relative to WT. An average of 20 alleles was sequenced for each genotype.](onc2010633f4){#fig4}

![Hic1 heterozygous mice develop crypt hyperplasia of the small intestine. (**a**) Shown are sections from small intestine stained with an antibody against Ki67 for mice as indicated. Scale bar=50 μm. (**b**) The number of crypts and villi per field were counted by two independent observers. Nine fields from three animals within each genotype were used in counting. Values represent the mean number of crypts per villi +/−s.e.m. in the small intestine. Asterisks indicate *P*\<0.05 by Student\'s *t*-test.](onc2010633f5){#fig5}

![Polyps display hallmarks of aberrant hic and wnt signaling. (**a**) Immunohistochemistry of paraffin-embedded polyps from small intestine (SI) and large intestine (LI) for antibodies as indicated. Genotypes of mice are as indicated. Scale bar=50 μm. (**b**) Real-time PCR expression for Sox9 in MEFs. Values represent the mean fold change±s.e.m. for triplicates. Genotypes of cells are as indicated. (**c**) Shown are western blot analyses of protein lysates from HCT116 cells transfected for 48 h with cDNA as indicated. (**d**) Immunohistochemistry using an antibody against Sox9 for paraffin-embedded polyps from small intestine (SI) and large intestine (LI). Genotypes of mice are as indicated. Scale bar=50 μm.](onc2010633f6){#fig6}
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